Pharvaris (NASDAQ:PHVS) Insider Sells $82,422.90 in Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Anna Nijdam sold 2,670 shares of Pharvaris stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $30.87, for a total value of $82,422.90. Following the transaction, the insider owned 46,275 shares in the company, valued at $1,428,509.25. This trade represents a 5.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Anna Nijdam also recently made the following trade(s):

• On Thursday, May 21st, Anna Nijdam sold 1,829 shares of Pharvaris stock. The shares were sold at an average price of $30.60, for a total value of $55,967.40.
• On Friday, May 22nd, Anna Nijdam sold 5,501 shares of Pharvaris stock. The shares were sold at an average price of $30.74, for a total value of $169,100.74.

Pharvaris Stock Performance

NASDAQ PHVS opened at $31.51 on Thursday. The stock has a market capitalization of $2.06 billion, a price-to-earnings ratio of -9.91 and a beta of -2.35. The stock’s 50 day moving average price is $29.49 and its two-hundred day moving average price is $27.48. Pharvaris N.V. has a 52 week low of $16.00 and a 52 week high of $33.33.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.12. On average, equities research analysts forecast that Pharvaris N.V. will post -3.22 EPS for the current year.

Analyst Ratings Changes

PHVS has been the topic of several research reports. Wolfe Research initiated coverage on Pharvaris in a research note on Thursday, April 9th. They issued an “outperform” rating and a $42.00 target price on the stock. Wall Street Zen upgraded Pharvaris from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Wedbush boosted their target price on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Pharvaris in a research note on Tuesday, March 3rd. Finally, Royal Bank Of Canada cut their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research note on Monday, April 6th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $49.18.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. General Atlantic L.P. increased its position in shares of Pharvaris by 6.6% during the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after purchasing an additional 500,000 shares during the last quarter. Foresite Capital Management IV LLC increased its position in shares of Pharvaris by 8.3% during the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock worth $119,226,000 after purchasing an additional 368,000 shares during the last quarter. venBio Partners LLC increased its position in shares of Pharvaris by 8.2% during the 3rd quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock worth $115,751,000 after purchasing an additional 350,000 shares during the last quarter. Deerfield Management Company L.P. increased its position in shares of Pharvaris by 21.1% during the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after purchasing an additional 425,000 shares during the last quarter. Finally, Commodore Capital LP increased its position in shares of Pharvaris by 26.5% during the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after purchasing an additional 507,043 shares during the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.